Immune activation may determine success of dual-target CAR T therapy in glioblastoma
Dual-target CAR T-cell therapy for recurrent glioblastoma (GBM), delivered directly into the cerebrospinal fluid (CSF), triggers a broad immune response, with natural killer (NK) cell activation linked to better patient outcomes ...
Jun 15, 2026
0
2









